Drug Profile
R 1577
Alternative Names: R-1577Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Class Antidementias
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in Europe (PO)
- 30 Sep 2004 Phase-I clinical trials in Alzheimer's disease in Europe (PO)
- 12 May 2004 Preclinical trials in Alzheimer's disease in Europe (PO)